Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Enhanced Valves Interventions and Safe AI Generated End Results

NCT07213531 · View on ClinicalTrials.gov ↗

Study Summary

This non-interventional study aims to use artificial intelligence to improve the prediction of transcatheter heart valve interventions and optimize patient outcomes. It is based on the analysis of retrospective data from various specialized centers worldwide.

Interventions

  • DIAGNOSTIC_TEST Medical imaging analysis via artificial intelligence algorithms

Study Locations (15)

Other

  • St Michael's Hospital Toronto — Toronto
  • St Paul's Hospital Vancouver — Vancouver
  • Centre Hospitalier Universitaire (CHU) de Bordeaux, 12 rue Dubernat 33404 Talence cedex — Bourdeaux
  • CHU Lille — Lille
  • CHU Marseille — Marseille
  • Centre Cardiologique du Nord Paris — Paris
  • Institut Cardiovasculaire Paris-Sud Paris — Paris
  • Centre Hospitalier Universitaire Rennes — Rennes
  • Clinque Pasteur Toulouse - France — Toulouse
  • University Medical Center Hamburg-Eppendorf — Hamburg
  • Heart Valve Center Mainz — Mainz
  • Istituto Clinico Città di Brescia — Brescia
  • San Raffaele Heart Valve Center Milan — Milan

New York

  • Montefiore Medical Center New York — New York

Quebec

  • Montreal Heart Institute, 5000 Rue Bélanger, Montréal — Montreal

Trial Details

FieldValue
Enrollment Target 21,000 participants
Start Date 2024-05-01
Est. Completion 2029-05

Sponsor

Montreal Heart Institute

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07213531

The ClinicalTrials.gov registry entry for NCT07213531 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 21,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montreal Heart Institute, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 8 conditions, with Heart Valve Disease appearing as the primary indexed condition, and to 1 intervention — of which Medical imaging analysis via artificial intelligence algorithms is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07213531 reports 15 study locations spanning 3 distinct geographic areas — top geographies include Other, New York, Quebec. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07213531 about?

NCT07213531 is a clinical study titled "Enhanced Valves Interventions and Safe AI Generated End Results". This non-interventional study aims to use artificial intelligence to improve the prediction of transcatheter heart valve interventions and optimize patient outcomes. It is based on the analysis of retrospective data from various specialized centers worldwide.

What is the current status of trial NCT07213531?

This trial is currently recruiting. The enrollment target is 21,000 participants. The study started on 2024-05-01. Estimated completion is 2029-05.

What conditions does trial NCT07213531 study?

This clinical trial studies the following conditions: Heart Valve Disease, TAVI, M-TEER, TTVI, TMVI. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07213531?

The interventions under investigation include: Medical imaging analysis via artificial intelligence algorithms (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07213531?

This trial is sponsored by Montreal Heart Institute, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07213531 being conducted?

This trial has 15 study locations across New York, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial